- Market Capitalization, $K 135,070,784
- Shares Outstanding, K 2,368,001
- Annual Sales, $ 17,099 M
- Annual Income, $ 5,906 M
- 60-Month Beta 0.61
- Price/Sales 7.62
- Price/Cash Flow 20.74
- Price/Book 17.37
|Period||Period Low||Period High||Performance|
| || |
+2.04 (+3.88%)since 10/18/19
| || |
+3.28 (+6.40%)since 08/20/19
| || |
+10.92 (+25.02%)since 11/20/18
Bagsvaerd, Denmark, 20 November 2019 - Novo Nordisk is today hosting a Capital Markets Day where the company is introducing its strategic aspirations.
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of neighborhoods that may make...
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.
--- Each Company to Retain Rights to Co-Develop and
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Novo Nordisk is pleased to announce Ozempic(®) (semaglutide injection) is now publicly listed in the province of Quebec under the Régie de L'assurance Maladie du Québec (RAMQ). Ozempic(®) is a once-weekly...